secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001559053-23-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena reports Q3 net income of $21.9M; revenue surges to $84.9M on BMS license
--------------------------------------------------------------------------------

- Net income of $21.9M ($0.38 diluted EPS) vs net loss of $45.8M in Q3 2022; first nine months net loss of $79.6M.
- Revenue of $84.9M, primarily from $72.9M collaboration revenue from BMS tau license including $55M option fee.
- Cash and restricted cash $673.1M at Sept 30, 2023; guidance for year-end ~$600M.
- Upcoming milestones: PRX012 Phase 1 data by year-end 2023; AFFIRM-AL topline in 2024; prasinezumab Phase 2b in 2024.
- R&D expenses rose to $57.9M (+45% YoY) due to higher clinical trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905323000031/0001559053-23-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905323000031/prta-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001559053-23-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer